TD Cowen Reiterates Hold Rating on MacroGenics (MGNX)

TD Cowen analyst Boris Peaker reiterated a Hold rating on MacroGenics (NASDAQ: MGNX).

The analyst commented, "Cumulative tox in the Phase II TAMARACK update at ESMO led to worsened safety, including now 8 treatment-related patient deaths (up from 5 prior). While the preliminary 7.5-8.5-month rPFS appears competitive, we believe that if dosing is optimized and the program is successful, vobra duo may be limited to late-line patients if it's taken forward."

For an analyst ratings summary and ratings history on MacroGenics click here. For more ratings news on MacroGenics click here.

Shares of MacroGenics closed at $3.70 yesterday.

You May Also Be Interested In

• Evercore ISI Starts PBF Energy (PBF) at In Line
• Netflix (NFLX) PT Lowered to $105 at BofA Securities
• Protagonist Therapeutics (PTGX) PT Raised to $165 at Citizens as Icotyde Revenue Ramps